IP Library Granted Patent US 7,485,659
Granted Patent B2
US 7,485,659 · App. 11/696,116 · Granted Feb 3, 2009

Anticancer compositions, and methods of making and using the same

Assignee: Faustus Forschungs CIE, Translational Cancer Research GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,485,659
App. No.
11/696,116
Granted
Feb 3, 2009
Kind
B2
Abstract

Compositions, containing a ruthenium(III) complex and a heterocycle, methods for their manufacture, medicament containing these compositions and a kit. The invention relates to a composition (A), obtained by reacting a compound of the general formula (I) M 3−n−p−2pr [RUX 6−n−p−q−2r B n (H 2 O) p (OH) q (O) r ] 2r+1   (I) with a compound of the general formula (II) B′(HX′) s   (II). Furthermore, the invention relates to a composition (B), obtained by mixing a compound of the general formula (III) (B′H) 3−n−p−2pr [RUX 6−n−p−q−2r B n (H 2 O) p (OH) q (O) r ] 2r+1   (III) with a compound of the general formula (IV) MX′  (IV).

Claims (26)

1. A process of making a composition comprising a mixture of:

(i) a compound of the general formula (III):

(B′H) 3−n−p−2pr [RuX 6−n−p−q−2r B n (H 2 O) p (OH) q (O) r ] 2r+1   (III)

wherein

B and B′ are independently a monocyclic or multi-cyclic basic heterocycle chosen from imidazole, pyrazol, triazol, and indazol,

X represents a halide, pseudo-halide, HCO 3 − , or RCOO − in which R represents a substituted or unsubstituted C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl or a substituted or unsubstituted aryl, n=1 or 2, r=0, and each of p and q=0 or 1, or r=0.5 and each of p and q=0 or 0.5; and

(ii) a compound of the formula (IV):

MX′  (IV)

wherein

M represents an alkali metal cation or ammonia, and

X′ represents a halide, pseudo-halide, HCO 3 − , or RCOO − in which R is hydrogen or a substituted or unsubstituted C 1 -C 6 -alkyl or C 2 -C 6 -alkenyl or a substituted or unsubstituted aryl, phosphate, sulphate or acetate, said process comprising:

reacting a compound of the formula (I)

M 3−n−p−2pr [RuX 6−n−p−q−2r B n (H 2 O) p (OH) q (O) r ] 2r+1   (I)

with a compound of the formula (II)

B′(HX′) s   (II)

wherein

s is an integer of 1 or more, and M, B, X, B′, X′, n, p, q, and r are as defined above.

2. The process according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is less than 1.

3. The process according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is from 1:1.1 to 1:10.

4. The process according to claim 1 , wherein the molar ratio of the compound of the formula (I) to the compound of the formula (II) is from 1:2 to 1:5.

5. The process according to claim 1 , wherein said B and B′ are independently indazol.

6. The process according to claim 1 , wherein said X and X′ are halide.

7. The process according to claim 1 , wherein said M represents an alkali metal cation.

8. A process of making a composition comprising a mixture of indazolium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)], and sodium chloride, said process comprising reacting sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)]with indazolium hydrochloride under conditions to form said composition.

9. The process according to claim 8 , wherein the molar ratio of sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] and indazolium hydrochloride is less than 1.

10. The process according to claim 8 , wherein the molar ratio of sodium trans-[tetrachlorobis(1H-indazol)-ruthenate(III)] and indazolium hydrochloride is from about 1:1.1 to about 1:10.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2013
From: NIIKI PHARMA INC.
To: NIIKI PHARMA ACQUISITION CORP. 2
Reel/Frame 030838/0333 →
Priority Claims (1)
DE 101 03 565 · Jan 26, 2001 · national
Continuity (3)
Division 1062751900 · Jul 25, 2003
Continuation PCTEP020086300 · Jan 28, 2002
Related Publication 20070293557A1 · Dec 20, 2007